Nordic Life Science
Pharma
Latest Pharma News
H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. have announced that the European Commission has approved Rxulti (brexpiprazole) for the treatment of schizophrenia in adults. The approval follows the positive
Katarina Ageborg took over the role as Chief Executive Officer after Jan-Olof Jacke on August 1st 2018. Ageborg has been a member of AstraZeneca’s management team since 2011 and she
AstraZeneca and Merck & Co have announced that the European Medicines Agency has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).
The CDMO company has announced the launch of its standalone serialization service ahead of the introduction of the EU Falsified Medicines Directive (FMD). The new service is designed to offer
Our magazine and news site has a placing on “Pharma IQ’s Top 50 Pharmaceutical Blogs and Publications 2018”. Pharma IQ’s guide to the best pharmaceutical blogs, spanning pharma to biotech
AstraZeneca and MedImmune have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending a marketing authorisation of Imfinzi (durvalumab)
Clinical trials
The Swedish company has announced the results of a preclinical study confirming the potential for its NanoZolid technology for use
The company announces the status of the ongoing phase I/IIa clinical trial CANFOUR investigating the lead compound CAN04 (nidanilimab) and
The company announces results from its extension study of its Phase 2 study investigating the safety and immune responses of
The company begins clinical development of yet another potential new treatment of Parkinson’s disease with the enrollment of the first
The first patient has been dosed in a Phase 2 study evaluating the combination therapy of its cancer vaccine, CV301,
The company has reported positive results from a preclinical study in the field of acute kidney injury (AKI). The primary
Oncopeptides present updated interim data from the ongoing HORIZON trial with Ygalo at the 23rd Congress of The European Hematology
AstraZeneca and Eli Lilly and Company are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase
Follicum announces that all patients in the Phase IIa clinical trial with FOL-005 for stimulating hair growth have been recruited.
H. Lundbeck A/S and Takeda Pharmaceutical announce positive results from their pivotal study with vortioxetine in adults with Major Depressive
Lundbeck and Otsuka Pharmaceutical announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency
The company has anounced results from PIONEER 2, the second phase 3a trial with oral semaglutide for treatment of adults
The two pharma giants reports data which showed clinical improvement in median radiologic progression-free survival (rPFS) with Lynparza (olaparib) in
The Phase 2b trial with Betalutin (177Lu-satetraxetan-lilotomab) in third-line (3L) follicular lymphoma (FL) patients has been approved by the Regional
The trial, the second of two pivotal Phase III trials for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive
All subjects have been enrolled and dosed in the second and pivotal Phase 3 trial to confirm the clinical efficacy
Pharma articles
Immunotherapy is the 2016 Clinical Cancer Advance of the Year and a promising new strategy for treating cancer. But how far have we come? The American Society of Clinical Oncology
The high cost and uncertain outcomes of developing new drugs has taken a toll on research over the past several years. Few companies can take the hit of investing hundreds
Liquid biopsies, sequencing and upgraded software tools are among some of the recent and ongoing trends in cancer diagnostics. Developments in the diagnostic sector have vastly improved the ability to
The rapid development within nanotechnology drug delivery is creating new possibilities to treat common diseases and improving pharmaceuticals. Safety aspects and competitionwith established treatments are however some of the obstacles
Hans Lennernäs, professor in biopharmaceutics at Uppsala University, has extensive experience in developing drug delivery methods. NLS asked him about his research and ongoing activities in the field. He spoke
Much effort is being made to develop new medicines for diabetes and recent findings indicate the potential for new and improved pharmaceuticals. Diabetes is one of the largest global diseases
Profiles in Pharma
Ironically, there is less serendipity in the success Saeid Esmaeilzadeh and Ashkan Pouya have achieved as business-makers than there is
Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief
After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development
Sirpa Jalkanen is a professor in the Academy of Finland, board member of Orion, and cofounder with her husband, Markku
Academia and business don’t always mix, but Agnete B. Fredriksen of Norway has found the formula. While doing research for
Logistics
With a deadline looming to meet a new EU Falsification Medicines Directive (FMD) by 2019, there is no shortage of challenges for packaging experts. Besides satisfying EU requirements, drug manufacturers
Packaging is an often overlooked element of the life science supply chain but the industry needs to step up quality and foster innovation in order to keep up with developments